| 1.02 0.01 (0.99%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.47 | 1-year : | 1.69 |
| Resists | First : | 1.26 | Second : | 1.45 |
| Pivot price | 1.08  |
|||
| Supports | First : | 0.96 | Second : | 0.79 |
| MAs | MA(5) : | 1.02 |
MA(20) : | 1.12 |
| MA(100) : | 1.15 |
MA(250) : | 1.24 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 8.7 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 2.67 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ COCP ] has closed above bottom band by 19.7%. Bollinger Bands are 23.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.08 | 1.08 - 1.08 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.01 - 1.02 | 1.02 - 1.03 |
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Tue, 09 Jun 2026
Cocrystal Pharma Appoints James Sapirstein as New CEO – Leadership Transition and Company Details - Minichart
Tue, 09 Jun 2026
James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Thu, 04 Jun 2026
Cocrystal Pharma taps longtime biotech exec as its new CEO - The Business Journals
Wed, 03 Jun 2026
Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan - Stock Titan
Wed, 03 Jun 2026
Antiviral executive James Sapirstein takes helm at Cocrystal Pharma - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 9.12e+006 (%) |
| Held by Institutions | 30.7 (%) |
| Shares Short | 988 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.97e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 47.1 % |
| Return on Equity (ttm) | -62.5 % |
| Qtrly Rev. Growth | 225000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -103.09 |
| EBITDA (p.s.) | -3.22667e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 3.32 |
| Dividend | 0 |
| Forward Dividend | 192680 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|